The Integrating Application of Smart Wearable Devices and Artificial Intelligence Technology in Diabetes Management

Jiawei Zhang *

School of Biomedical Engineering, Shanghai Jiaotong University, Shanghai, 200240, China

* Corresponding Author Email: gallium7@sjtu.edu.cn

Abstract. Diabetes is a pervasive global health challenge, requiring continuous glucose monitoring and personalized management to prevent severe complications. Traditional methods like fingerstick testing are often intrusive, inconvenient, and lack real-time monitoring. This paper explores the transformative potential of integrating smart wearable devices with artificial intelligence (AI) for more patient-friendly, personalized diabetes management. It systematically analyzes the respective application models: wearable devices (e.g., smartwatch-integrated sweat patches, IoT-enabled optical monitors) for non-invasive, continuous data acquisition, and AI technologies (e.g., deep learning, quantum-inspired models) for data analysis, accurate prediction, and personalized therapy optimization. Furthermore, the paper demonstrates a comprehensive integration mechanism: a four-layered architecture from multi-modal data acquisition and fusion to AI-powered analytics and to real-time intervention. The study considers that this system provides a dynamic, proactive, and highly personalized management, significantly shifting the management from passive health care to active health optimization. Though it still has limitations regarding data accuracy, privacy security, and public adoption, the integration of wearable devices and AI undeniably paves the way for intelligent, convenient, and personalized chronic disease management.

Keywords: Diabetes, wearable devices, artificial intelligence, integration.

1. Introduction

Diabetes is a chronic metabolic disease, affecting a large number of people worldwide [1]. And the number is still growing now. Since uncontrolled diabetes can enhance the possibilities of heart failure, kidney damage, and blindness, real-time and continuous glucose monitoring is necessary for diabetes patients [2]. However, traditional glucose monitoring methods like fingerstick testing, which penetrate the skin, are uncomfortable and inconvenient and have limitations regarding personalized therapy and real-time data [3]. The weakness of existing glucose monitoring methods promotes the fast progress of biological sensors and Internet of Medical Things (IoMT), which give rise to the emergence of more intelligent and convenient wearable devices [4, 5]. At the same time, the rapid development of artificial intelligence significantly improves the capability to process and analyze data. In healthcare, artificial intelligence (AI) has already been employed to achieve efficient and accurate data analysis and upgrade the prevention, diagnosis, and therapy of different chronic diseases [6]. A 2024 study demonstrated that the combination of wearable devices and AI technology can successfully realize the early detection of gestational diabetes (GDM). Conducted in South Africa, the research produced interpretable predictions of GDM-associated biomarker values up to 13-16 weeks before clinical diagnosis [7]. Consequently, it is obvious that the combination of smart wearable devices and artificial intelligence technology provides a new solution for diabetes management. Through continuous monitoring, accurate data analysis, and personalized service, the system can increase diabetes management efficiency and patient compliance. Fig. 1 illustrates the proposed framework comprising wearable devices and AI technology. This research aims to explore the respective application models, integration mechanism, current technical limitations, and future development orientation of smart wearable devices and artificial intelligence technology in diabetes management.




Figure 1. Overview of the wearable devices equipped with artificial intelligence (Photo credit: Original)

2. Respective Application Models

2.1. Wearable Devices

Wearable devices, or simply wearables, are smart electronic systems consisting of a target receptor and a transducer, which are built into a variety of personal belongings, including clothes, watches, rings, and other common items that consumers wear [8]. They can be used to continuously monitor users' conditions and gain and transfer the data. Hence, these techniques are increasingly applied in healthcare, including diabetes management.

2.1.1. Smartwatch-Integrated Microfluidic Sweat Patch

This device integrates a microfluidic patch with a smartwatch for blood glucose monitoring. The patch uses a Tesla valve design, autonomously and continuously drawing sweat to a sensing chamber. Here, glucose oxidase and an oxygen-sensitive dye react with sweat glucose in an optical hydrogel sensor. The reaction alters fluorescence intensity, which is optically excited and read by the smartwatch's micro-LED and photodetector module. An onboard processor digitizes, filters, and converts the signals into physiological data, which is displayed on the watch and transmitted via Bluetooth/Wi-Fi to a paired smartphone or cloud. Tested by experiments, the system demonstrated a statistically significant correlation with blood glucose levels, reliably tracking postprandial glucose excursions in human subjects over 7 hours, validating its use for continuous non-invasive monitoring [9].

2.1.2. IoT-Enabled Non-Invasive Optical Monitor (iGM Framework)

The iGM framework is a wrist-worn device that employs Red and Near-Infrared (R-NIR) spectroscopy for non-invasive estimation. It operates by shining R-NIR light into the skin and measuring the reflected light intensity with a photodiode, as blood glucose levels modulate this intensity. An on-board ESP32 microcontroller processes the signal and calculates a glucose value using open-source algorithms. Processed data is streamed in real-time to an AWS IoT cloud platform via Wi-Fi (MQTT protocol) and can be shown on a small OLED display. By verification of experimental test, the device achieved a high accuracy of 98.82% after 10 hours of fasting and 98.04% after a meal when compared to a commercial finger-prick glucometer (Accu-Check Active), demonstrating its potential for reliable non-invasive monitoring [10].

2.1.3. Passive UHF RFID-CSRR Glucose Sensor

This platform is a fully passive and battery-free sensor created through the merger of a Complementary Split-Ring Resonator (CSRR) and a UHF RFID antenna. It operates on dielectric sensing principles: glucose concentration alters the solution's permittivity, which changes the CSRR's resonance. This shift capacitively couples to the antenna, modifying its impedance and backscatter characteristics. A commercial RFID reader interrogates the sensor wirelessly, measuring the variation in the minimum power required to activate it or its maximum read range. The reader then transmits this data to a computer for analysis. Experimental results demonstrated a highly linear response (R^2 = 0.986) in the sensor, with its read range varying from 6.23 m to 4.67 m over a glucose concentration of 50 to 200 mg/dL, confirming its effectiveness as a passive, wireless solution for concentration monitoring [11].

These three devices exemplify the diverse smart wearable devices in diabetes management. The smartwatch offers a holistic, multi-parameter, and truly continuous monitoring solution directly from the body, representing the highest level of integration and user convenience. The iGM framework demonstrates a direct non-invasive approach leveraging IoT for real-time data streaming, though it may face challenges with accuracy due to inherent optical signal variability. The passive RFID sensor showcases an ultra-low-power, battery-free paradigm ideal for blood glucose sensing applications, but its operation is not continuous and requires proximity to a dedicated reader, limiting its practicality for dynamic, daily life monitoring. Consequently, each technique has respective advantages and disadvantages, presenting a unique trade-off between integration level, power autonomy, convenience, and sensing methodology.

Through the above three typical technologies, it is obvious that wearable devices offer significant advantages for diabetes management, including the potential for non-invasive or minimally invasive continuous monitoring, which provides unparalleled insights into glucose trends. They empower patients with real-time feedback, enhance compliance through convenience, and facilitate personalized therapy and early warning alerts. However, challenges remain, revolving around the accuracy and reliability of non-invasive methods compared to established blood-based measurements. Other limitations include cost, the need for regular calibration of some devices, long-term stability of sensors, data security, and ensuring that the technology is accessible and user-friendly for all patient demographics, especially the elderly.

2.2. Artificial Intelligence Technologies

Artificial Intelligence (AI) is defined as the ability of machines to use electronic output devices to communicate with humans without revealing the identity that they are not humans [12]. Given its powerful data analysis and predictive capabilities, AI has great potential in disease risk assessment, therapy personalization, and treatment optimization [13].

2.2.1. Stacked Convolutional Neural Network (Stack-CNN) for High-Precision Prediction

The Stacked Convolutional Neural Network (Stack-CNN) model shows a significant advancement in using a deep learning model to make the risk assessment of diabetes. Instead of processing data in a continuous stream like wearables, it can rapidly analyze and evaluate a set of patients' data and achieve a form of "snapshot" real-time analysis. Its ability to make real-time analysis relies on its highly optimized structure: once trained by previous data, it can process a new patient's physiological data (e.g., blood glucose, BMI, age) immediately. The first step of data processing is to filter and fill in the missing data to ensure it is clean and ready to use. The model's analytical ability is greatly improved by a complicated feature selection system that acts like a collective decision-making process. This system employs six different methods to first identify the clinical features and then retains only the key points, like weight loss, thirst, and blood sugar levels. By filtering out the less important data it reduces noise and enhances the model's generalization.

For personalized treatment, the high accuracy (>98%) of Stack-CNNs ensures extremely reliable diagnosis, even in cases with non-typical symptoms. Therefore, it helps doctors to generate correct

interventions from the beginning. More importantly, techniques like SHAP (Shapley Additive explanations) can make the model's decisions clear and understandable by quantifying how much each feature contributes to the prediction. For example, through this technique, a doctor can easily see that a patient's high-risk evaluation is mainly caused by elevated postprandial glucose and BMI. This directly informs doctors of the most critical and influential factors for each patient, enabling doctors to optimize and personalize the treatment plans, such as making specific adjustments to diet or prescribing metformin [14].

2.2.2. Quantum-Inspired Stacked Integrated Concept Graph Model (QISICGM) for Enhanced Pattern Recognition

The Quantum-Inspired Stacked Integrated Concept Graph Model (QISICGM) offers a new method for analyzing complex diabetic data by emulating quantum computational principles on typical and traditional hardware. Its highly efficient inference engine is capable of processing data at approximately 8.5 rows per second on a standard CPU, making real-time monitoring possible. Therefore, it is suitable for integration into clinical workflows for immediate evaluation. First, data is transformed through a quantum-inspired phase feature map, which encodes classical features like glucose and BMI into a rich, non-linear trigonometric space (cosine and sine waves). Through this data transformation, the model's ability to distinguish the subtle differences among various patterns is improved. The following is the core innovation: the self-improving concept graph, which models a network with the patients as nodes, connecting individuals with similar clinical features. This graph continuously refines itself through iterative learning, effectively and accurately identifying the diabetic and non-diabetic patients.

Personalization is achieved through this graph-based structure. When a new patient is analyzed, the model evaluates their position within the concept graph and examines their nearest "neighbors" – patients with the most similar characteristics. By analyzing the outcomes and treatments of these similar patients, the QISICGM can infer potential risk trajectories and suggest interventions that have proven effective for comparable cases. This facilitates a comparative personalized medicine approach. Furthermore, the model is well-calibrated, meaning its predicted probabilities of diabetes risk are accurate and trustworthy. This allows clinicians to optimize resource allocation by stratifying patients into precise risk categories (low, medium, high) and tailoring monitoring intensity and preventive measures accordingly [15].

2.2.3. Remote Monitoring System with Integrated Wearables for Dynamic Management

This AI-driven framework moves beyond periodic assessment to enable genuine. continuous, real-time monitoring of diabetes. It integrates data from a suite of smart wearables and personal health devices, such as Continuous Glucose Monitors (CGMs), smartwatches (tracking physical activity and heart rate), and Bluetooth-enabled blood pressure cuffs. This creates a continuous, automated stream of physiological data transmitted wirelessly to a central analysis platform. At the heart of this system is a real-time processing core, which uses robust machine learning models, such as Random Forests. These models are first trained on large historical datasets to identify different patterns that indicate hyperglycemia, hypoglycemia, or other health risks. Once established, the system continuously analyzes the incoming data of patients based on these certain patterns. Therefore, the efficiency of risk identification has been greatly improved.

The core achievement of this system lies in its personalization and optimization of the treatment plans. When the system detects an abnormal signal—such as a rapid drop in glucose levels indicating potential hypoglycemia—it can make immediate interventions. These include sending real-time alerts to the patient's smartphone, urging them to consume sugar quickly. For long-term optimization, the AI integrates the collected data and predicts the trends to provide personalized feedback. It can identify consistent rises in patients' glucose after a meal, enabling individualized recommendations for diet adjustments. This creates a cycle of continuous monitoring, dynamic feedback, and behavioral intervention. It not only provides patients a chance to take charge of their daily life, but also gives doctors a rich, continuous stream of information to perfect and personalize the treatment plans [16].

Each of the three AI models shows unique and significant strengths in diabetes management. The Stack-CNN model excels at making precise diagnoses from a series of patients' data, acting as a highly reliable initial diagnostic tool. The QISICGM framework enhances the accuracy of predictions by placing a patient within a network of similar individuals and using a complicated layer of pattern cognition. Meanwhile, the remote monitoring system shifts the inconsistent assessment to continuous, dynamic management and directly offers real-time interventions. While the Stack-CNN and QISICGM mainly enhance the precision of clinical decisions, such as diagnosis and the prediction of disease development, the remote monitoring system focuses on improving the quality of patients' lives in the period of treatment.

In conclusion, AI's integration into diabetes management shows significant advantages, including enhancing the accuracy of prediction and greatly enhancing the personalization of treatment plans. These technologies empower both doctors and patients, therefore leading to more efficient resource contribution and improved self-management. However, challenges remain, such as the risks of data leakage and privacy exposure, the public adoption of advanced AI models, and the need for more reliable clinical validation among diverse populations. Addressing these current barriers is significant for the equitable and effective global application of AI-driven diabetes care.

3. Integration mechanism




Figure 2. The process of integrating mechanism between wearable devices and AI (Photo credit: Original)

Fig. 2 illustrates the whole process of integrating mechanism between wearable devices and AI, containing 4 main layers: Perception Layer, Data Integrating and Processing Layer, AI Analysis and Decision Layer, and Intervention and Feedback Layer. This interaction creates a dynamic digital diabetes management system where smart wearable devices act as pervasive sensory organs, collecting real-time physiological data, and AI serves as the analytical brain, transforming this data

into a quantifiable and understandable index. The efficiency of this system depends on a complicated, multi-layered architecture containing data acquisition, integration, intelligent analysis, and personalized intervention.

The integration mechanism is built on a multi-modal data acquisition and fusion module, which contains a perception layer and a data processing layer. A variety of wearable devices, including smartwatches and Continuous Glucose Monitors (CGMs), generate massive amounts of high-frequency, sequential, and different-format data. CGMs record glucose concentrations every 1 to 5 minutes, while smartwatches collect patients' daily data such as activity levels and sleep quality. A critical technical challenge is integrating all these different data streams onto the same timeline. This can be addressed by advanced data processing techniques, such as a redesigned API handler leveraging IBM API Hub. It efficiently integrates and stores the data streams in a centralized PostgreSQL database. The process involves filtering clinical data, digitalizing the patient-reported behavioral information, and integrating it with dynamic glucose readings from CGMs [17]. The core innovation of this module is its ability to break down data silos, thus creating a foundation for personalized glucose management.

The core of this mechanism is an AI-powered analytical and decision-making layer. Here, artificial intelligence models extract meaningful patterns and generate precise predictions from complex data. For short-term glucose prediction, machine learning models are adept at handling sequential data. Techniques such as Kalman filtering and normalization can first analyze historical and real-time CDM data. Then, AI models like the IPSO-ELM model can use the processed data to make high-accuracy, short-term predictions [18]. Furthermore, for long-term glucose predictions and therapy personalization, Reinforcement Learning (RL) algorithms are increasingly explored. In an RL framework, the AI models can generate the most suitable actions, such as insulin dosing suggestions, by interacting with a simulated environment of the patient's physiology. When improved with online learning ability, the RL model can predict long-term trends in dynamical glucose concentration [19]. This facilitates a shift from standardized, rigid guidelines to adaptive and truly individualized treatment plans.

The ultimate expression of this integration is a real-time intervention and feedback layer. This system uses AI algorithms to directly automate therapy, including offering immediate alerts, automatically controlling an insulin pump, and setting personalized therapy. Model Predictive Control (MPC) is a predominant AI technique, which continuously predicts future glucose trajectories based on real-time CGM data and automatically adjusts the insulin infusion rate of a connected pump to maintain glucose within a target range, while incorporating safety constraints to prevent hypoglycemia [20, 21]. Even in open-loop systems, where decisions require human approval, the feedback is immediate: AI-driven insights are delivered to patients and clinicians via mobile applications, providing real-time alerts and personalized recommendations for diet, exercise, or medication.

In essence, the integration mechanism between smart wearables and AI establishes a dynamic, closed-loop intelligent system. The true fusion is achieved through a continuous cycle of data flow and feedback that creates an adaptive management ecosystem. Wearables function as the perception layer, continuously acquiring raw, multi-modal physiological data. This data is not only stored in a database, but also fused with the digital patterns of the patient's status, which have been digitalized and processed already. AI then acts as the brain, where advanced algorithms process the integrated data into predictive trends and specific actions. The critical step that completes the loop is the translation of these AI-driven decisions into real-time, guided interventions—such as small adjustments to an insulin pump or personalized behavioral recommendations. These interventions directly influence the patient's physiological condition, which is then measured again by the wearables, generating new data for the AI models. This integration mechanism enables the system to move beyond static, passive patterns to a paradigm of continuous, self-learning, and personalized optimization.

4. Conclusion

This study comprehensively discusses the integration application of smart wearable devices and artificial intelligence technology in diabetes management through several typical models, demonstrating the transformative potential of this integrated system. The research presents three representative wearable devices: smartwatch-integrated sweat patches, IoT-enabled optical monitors, and passive UHF RFID sensors, each offering different advantages in non-invasive, continuous glucose monitoring. These devices not only enhance patient comfort, convenience, and compliance but also generate high-frequency, real-time physiological data critical for proactive disease management. On the AI front, the study highlights three advanced models: the Stacked CNN for high-precision diagnostic prediction, the Quantum-Inspired Stacked Integrated Concept Graph Model (QISICGM) for pattern recognition and comparative personalized medicine, and a remote monitoring system that enables real-time intervention and behavioral feedback. These AI frameworks significantly improve predictive accuracy, support individualized treatment planning, and facilitate dynamic, data-driven decision-making. The integration mechanism outlined in this paper—spanning multi-modal data acquisition, AI-powered analytics, and real-time intervention—establishes a robust, multi-layered architecture for intelligent diabetes care. This system shifts the paradigm from reactive, episodic treatment to continuous, personalized health optimization. Importantly, the fusion of wearables and AI empowers patients with actionable insights, fostering greater self-management and engagement.

However, this system still faces numerous challenges. Smart wearable devices still have limitations in accuracy, long-term reliability, and usage scenarios. AI technology involves the problems of data security, personal privacy, and the acceptance by the public. Future work should focus on improving sensor precision, ensuring data security, and conducting large-scale clinical validations across diverse populations.

In conclusion, the fusion of artificial intelligence technologies and wearable devices is not only an additive combination but a transformative integration that creates an intelligent, responsive system for diabetes management. By seamlessly integrating data acquisition, intelligent analysis, and timely intervention, this system enables unprecedented levels of personalization and automation in chronic disease care.

References

[1] Zhu Taiyu, Kuang Lei, Daniels John, et al. IoMT-Enabled Real-Time Blood Glucose Prediction with Deep Learning and Edge Computing. IEEE Internet of Things Journal, 2023, 10 (5): 3706 - 3719.

[2] Joshi Amit M., Jain Prateek, Mohanty Saraju P., et al. iGLU 2.0: A New Wearable for Accurate Non-Invasive Continuous Serum Glucose Measurement in IoMT Framework. IEEE Transactions on Consumer Electronics, 2020, 66 (4): 327 - 335.

[3] Ghosh Neha, Verma Saurabh. Technological advancements in glucose monitoring and artificial pancreas systems for shaping diabetes care. Current Medical Research and Opinion, 2024, 40 (12): 2095 – 2107.

[4] Rodríguez-Rodríguez Ignacio, Rodríguez José-Víctor, Campo-Valera María. Applications of the Internet of Medical Things to Type 1 Diabetes Mellitus. Electronics, 2023, 12 (3): 756.

[5] Cheng Yuemeng, Wang Kan, Xu Hao, et al. Recent developments in sensors for wearable device applications. Anal Bioanal Chem, 2021, 413: 6037 – 6057.

[6] Murala Dileep Kumar, Panda Sandeep Kumar, Dash Sujata Priyambada. MedMetaverse: Medical Care of Chronic Disease Patients and Managing Data Using Artificial Intelligence, Blockchain, and Wearable Devices State-of-the-Art Methodology. IEEE Access, 2023, 11: 138954 - 138985.

[7] Kolozali Şefki, White Sara L., Norris Shane, et al. Explainable Early Prediction of Gestational Diabetes Biomarkers by Combining Medical Background and Wearable Devices: A Pilot Study with a Cohort Group in South Africa. IEEE Journal of Biomedical and Health Informatics, 2024, 28 (4): 1860 - 1871.

[8] Iqbal Sheikh M. A., Mahgoub Imadeldin, Du E, et al. Advances in healthcare wearable devices. npj Flexible Electronics, 2021, 5: 9.

[9] Cheong Sunah, Jonghyun Chae, Lee Hwiwon, et al. Microfluidic tesla valve sweat patch integrated smartwatch for optical continuous monitoring of glucose, oxygen, and heart rate. Biosensors and Bioelectronics, 2025, 289: 117925.

[10] K. M Abubeker, R Ramani., Krishnamoorthy Raja, et al. Internet of Things enabled open source assisted real-time blood glucose monitoring framework. Scientific Reports, 2024, 14: 6151.

[11] Hussain Tauseef, Abounasr Jamal, Gil Ignacio, et al. Capacitively Coupled CSRR and H-Slot UHF RFID Antenna for Wireless Glucose Concentration Monitoring. Sensors, 2025, 25 (18): 5651.

[12] Jiang Yuchen, Li Xiang, Luo Hao, et al. Quo vadis artificial intelligence? Discov Artif Intell, 2022, 2: 4.

[13] Campanella Sara, Paragliola Giovanni, Cherubini Valentino, et al. Towards Personalized AI-Based Diabetes Therapy: A Review. IEEE Journal of Biomedical and Health Informatics, 2024, 28 (11): 6944 - 6957.

[14] Young Kenneth G. II. Quantum-Inspired Stacked Integrated Concept Graph Model (QISICGM) for Diabetes Risk Prediction. arXiv, 2025: 2509. 12259.

[15] Ali Jaward, Hussain Manzoor, Hendrawati Trisiani Dewi. A Comprehensive Remote Monitoring System for Automated Diabetes Risk Assessment and Control Through Smart Wearables and Personal Health Devices. Engineering Proceedings, 2025, 107 (1): 91.

[16] Islam Md Tanvir, Miah Abu Saleh Musa, Raihan M., et al. DiaBD: A novel benchmark dataset for diabetes prediction. Alexandria Engineering Journal, 2025.

[17] Vince S. Siu, Carla Agurto, Michael Graziano, et al. A Cloud-Based, Multi-Modal Data Architecture for Post-Transplant Diabetes Management. 2025 IEEE International Conference on Digital Health (ICDH), 2025: 1 - 9.

[18] Yu Liling, Zhang Gangping, Xu Binfeng, et al. Extreme Learning Machine Algorithm Based on IPSO for Prediction of Blood Glucose Concentration in Patients with Type 1 Diabetes. 2022 7th International Conference on Computational Intelligence and Applications (ICCIA), 2022: 113 - 117.

[19] Lim Min Hyuk, Lee Woo Hyung, Jeon Byoungjun, et al. A Blood Glucose Control Framework Based on Reinforcement Learning with Safety and Interpretability: In Silico Validation. IEEE Access, 2021, 9: 105756 - 105775.

[20] Toffanin Chiara, Magni Lalo, Cobelli Claudio. Artificial Pancreas: In Silico Study Shows No Need of Meal Announcement and Improved Time in Range of Glucose with Intraperitoneal vs. Subcutaneous Insulin Delivery. IEEE Transactions on Medical Robotics and Bionics, 2021, 3 (2): 306 - 314.

[21] Castillo A., Villa-Tamayo M.F., Pryor E., et al. Deep Neural Network Architectures for an Embedded MPC Implementation: Application to an Automated Insulin Delivery System. IFAC-PapersOnLine, 2023, 56 (2): 11521 - 11526.